George C Tsokos Selected Research

Autoantigens

1/2017	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.
6/2015	T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.
3/2011	Abnormalities of T cell signaling in systemic lupus erythematosus.
9/2003	T cell abnormalities in human and mouse lupus: intrinsic and extrinsic.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

George C Tsokos Research Topics

Disease

138	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2024 - 01/2002
48	Autoimmune Diseases (Autoimmune Disease) 01/2024 - 01/2004
29	Inflammation (Inflammations) 01/2024 - 11/2003
19	Ischemia 10/2017 - 06/2002
16	Lupus Nephritis 01/2024 - 07/2008
11	Infections 10/2023 - 03/2005
11	Rheumatoid Arthritis 01/2021 - 05/2002
11	Hemorrhage 01/2016 - 08/2004
9	Nephritis 10/2021 - 09/2009
9	Glomerulonephritis 01/2018 - 09/2008
9	Reperfusion Injury 10/2017 - 01/2004
8	Wounds and Injuries (Trauma) 01/2020 - 03/2007
7	Lung Injury 01/2021 - 02/2005
7	Mesenteric Ischemia 01/2017 - 12/2003
6	Kidney Diseases (Kidney Disease) 11/2023 - 07/2010
6	Arthritis (Polyarthritis) 01/2023 - 11/2003
6	Proteinuria 01/2023 - 02/2011
6	Neoplasms (Cancer) 11/2018 - 10/2005
5	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2024 - 12/2011
5	Rheumatic Diseases (Rheumatism) 01/2024 - 11/2003
5	Psoriatic Arthritis 01/2024 - 12/2011
5	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2021 - 12/2015
4	Experimental Arthritis 01/2023 - 11/2003
4	COVID-19 01/2021 - 06/2020
4	Hypotension (Low Blood Pressure) 01/2013 - 02/2007
4	Hemorrhagic Shock 01/2013 - 02/2007
3	Fibrosis (Cirrhosis) 01/2023 - 07/2015
3	Hypoxia (Hypoxemia) 04/2010 - 04/2003
2	Thrombosis (Thrombus) 01/2023 - 06/2009
2	Virus Diseases (Viral Diseases) 11/2021 - 05/2014
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 11/2020 - 06/2020
2	Acute Lung Injury 11/2020 - 06/2020
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2019 - 01/2018

Drug/Important Bio-Agent (IBA)

38	Interleukin-2 (IL2)IBA 10/2022 - 05/2002
36	AutoantibodiesIBA 01/2024 - 01/2004
32	Complement System Proteins (Complement)IBA 11/2023 - 01/2004
26	CytokinesIBA 01/2023 - 09/2005
24	Interleukin-17 (Interleukin 17)IBA 01/2024 - 12/2008
24	Proteins (Proteins, Gene)FDA Link 01/2023 - 10/2002
13	AntibodiesIBA 01/2023 - 01/2004
12	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2015 - 01/2002
11	Antigen-Antibody Complex (Immune Complex)IBA 11/2023 - 10/2012
11	CalciumIBA 10/2021 - 12/2003
11	Syk KinaseIBA 01/2021 - 03/2007
10	Cyclic AMP Response Element ModulatorIBA 01/2024 - 12/2011
10	AntigensIBA 01/2023 - 09/2005
9	Transcription Factors (Transcription Factor)IBA 01/2024 - 02/2007
9	zeta chain antigen T cell receptor (TCR zeta chain)IBA 11/2005 - 01/2002
7	Interleukin-23 (Interleukin 23)IBA 01/2024 - 09/2009
7	Immunoglobulin G (IgG)IBA 01/2023 - 04/2005
7	Messenger RNA (mRNA)IBA 11/2012 - 06/2002
6	Biomarkers (Surrogate Marker)IBA 01/2024 - 11/2004
5	Calcium-Calmodulin-Dependent Protein Kinase Type 4IBA 01/2023 - 10/2012
5	KN 93IBA 01/2023 - 02/2011
5	DNA (Deoxyribonucleic Acid)IBA 12/2018 - 05/2002
5	CD55 Antigens (Decay Accelerating Factor)IBA 01/2013 - 09/2007
5	Caspase 3 (Caspase-3)IBA 09/2007 - 12/2003
4	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 10/2018
4	Interleukin-6 (Interleukin 6)IBA 01/2022 - 05/2011
4	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 02/2008
4	AutoantigensIBA 01/2017 - 09/2003
4	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 07/2013 - 11/2005
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2012 - 06/2010
3	anti-dsDNA autoantibodyIBA 01/2023 - 01/2013
3	Calcium-Calmodulin-Dependent Protein KinasesIBA 10/2021 - 12/2011
3	Monoclonal AntibodiesIBA 01/2021 - 09/2005
3	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2021 - 09/2007
3	LigandsIBA 01/2021 - 05/2014
3	Interferon Type IIBA 12/2020 - 07/2011
3	fostamatinibIBA 11/2020 - 07/2015
3	EnzymesIBA 01/2020 - 05/2014
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020 - 02/2011
3	RNA Splicing FactorsIBA 12/2018 - 01/2013
3	Signaling Lymphocytic Activation Molecule FamilyIBA 01/2017 - 01/2016
3	Complement C3 (C3 Complement)IBA 01/2017 - 09/2007
3	Complement Receptors (Complement Receptor)IBA 10/2015 - 12/2004
3	Therapeutic UsesIBA 11/2014 - 12/2003
3	Immunoglobulin M (IgM)IBA 12/2013 - 02/2009
3	Protein Isoforms (Isoforms)IBA 03/2013 - 05/2010
3	VaccinesIBA 02/2013 - 11/2006
3	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2011 - 09/2004
3	Adenosine Triphosphate (ATP)IBA 09/2007 - 02/2005
3	geldanamycinIBA 09/2007 - 08/2004
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 09/2007 - 02/2005
2	Immunomodulating AgentsIBA 10/2023 - 01/2023
2	2,6-dinitrotoluene (DNT)IBA 10/2022 - 01/2021
2	GlutaminaseIBA 01/2022 - 11/2019
2	NAD (NADH)IBA 01/2022 - 01/2020
2	Guanine Nucleotide Exchange Factors (Guanine Nucleotide Exchange Factor)IBA 01/2021 - 12/2018
2	Peptides (Polypeptides)IBA 01/2021 - 01/2017
2	InterferonsIBA 01/2021 - 12/2020
2	Interleukin-12 (IL 12)IBA 01/2021 - 10/2018
2	Mucin-1 (CA 15-3 Antigen)IBA 01/2021 - 06/2020
2	Complement Inactivating AgentsIBA 01/2021 - 09/2005
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2020 - 10/2011
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2019 - 01/2018

Therapy/Procedure

16	Therapeutics 10/2023 - 05/2002
6	Resuscitation 01/2013 - 08/2004
3	Intravenous Injections 01/2013 - 07/2011
2	Fecal Microbiota Transplantation 07/2022 - 01/2022